Curtis A Engelhart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6857151/publications.pdf

Version: 2024-02-01

759233 940533 18 625 12 16 citations h-index g-index papers 20 20 20 785 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genome-wide gene expression tuning reveals diverse vulnerabilities of M.Âtuberculosis. Cell, 2021, 184, 4579-4592.e24.	28.9	131
2	Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nature Communications, 2019, 10, 4970.	12.8	82
3	Chemical Genetic Interaction Profiling Reveals Determinants of Intrinsic Antibiotic Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	70
4	CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis. Nature Microbiology, 2022, 7, 766-779.	13.3	68
5	Opposing reactions in coenzyme A metabolism sensitize <i>Mycobacterium tuberculosis</i> to enzyme inhibition. Science, 2019, 363, .	12.6	53
6	Dual inhibition of the terminal oxidases eradicates antibioticâ€tolerant <i>Mycobacterium tuberculosis</i> . EMBO Molecular Medicine, 2021, 13, e13207.	6.9	47
7	Discovery and Structure–Activity-Relationship Study of <i>N</i> -Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β- <scp>d</scp> -ribose 2′-Oxidase. Journal of Medicinal Chemistry, 2018, 61, 9952-9965.	6.4	29
8	Targeting protein biotinylation enhances tuberculosis chemotherapy. Science Translational Medicine, 2018, 10, .	12.4	24
9	Investigation of $(\langle i \rangle S \langle i \rangle)$ -(\hat{a}^{*})-Acidomycin: A Selective Antimycobacterial Natural Product That Inhibits Biotin Synthase. ACS Infectious Diseases, 2019, 5, 598-617.	3.8	22
10	Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of <i>Mycobacterium tuberculosis</i>	3.5	19
11	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity. Journal of Medicinal Chemistry, 2022, 65, 6903-6925.	6.4	16
12	Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target. Journal of Medicinal Chemistry, 2022, 65, 409-423.	6.4	15
13	Avoiding Antibiotic Inactivation in <i>Mycobacterium tuberculosis</i> by Rv3406 through Strategic Nucleoside Modification. ACS Infectious Diseases, 2018, 4, 1102-1113.	3.8	14
14	Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in <i>Mycobacterium tuberculosis</i> . ACS Infectious Diseases, 2021, 7, 141-152.	3.8	13
15	Antitubercular 2-Pyrazolylpyrimidinones: Structure–Activity Relationship and Mode-of-Action Studies. Journal of Medicinal Chemistry, 2021, 64, 719-740.	6.4	9
16	Rediscovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in Mycobacterium tuberculosis. Journal of Biological Chemistry, 2021, 296, 100257.	3.4	9
17	Re-discovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in. Journal of Biological Chemistry, 2021, , .	3.4	0
18	Twoâ€way regulation of protein expression for identification and validation of onâ€ŧarget inhibitors of <i>Mycobacterium tuberculosis</i> . FASEB Journal, 2022, 36, .	0.5	0